• 1
    Balm M, Hammack J. Leptomeningeal carcinomatosis. Arch Neurol. 1996; 53: 626632.
  • 2
    Grant R, Naylor B, Greenberg HS, et al. Clinical outcome in aggressively treated meningeal carcinomatosis. Arch Neurol. 1994; 51: 457461.
  • 3
    Grossman S, Moynihan T. Neurologic complications of systemic cancer: neoplastic meningitis. Neurol Clin. 1991; 9: 843856.
  • 4
    Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol. 1993; 11: 561569.
  • 5
    Hitchens R, Bell D, Woods R, et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol. 1987; 5: 16551662.
  • 6
    Glantz M, Jaeckle KA, Chamberlain MC, et al. A randomized trial of a slow-release formulation of cytarabine for the treatment of lymphomatous meningitis. J Clin Oncol. 1999; 17: 31103116.
  • 7
    Glantz M, Jaeckle K, Chamberlain MC, et al. A randomized trial comparing intrathecal sustained-release ara-C (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999; 11: 33943402.
  • 8
    Chamberlain M, Dirr L. Involved field radiotherapy and intra-Ommaya methotrexate/ara-C in patients with AIDS-related lymphomatous meningitis. J Clin Oncol. 1993; 11: 19781984.
  • 9
    Fulton D, Levin V, Gutin P. Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors. Cancer Chemother Pharmacol. 1982; 8: 285291.
  • 10
    Gutin P, Weiss H, Wiernik P, et al. Intrathecal N, N′, N″-triethylenethiophosphoramide [thio-TEPA (NSC 6369)] in the treatment of malignant meningeal disease. Phase I-II study. Cancer. 1976; 38: 14611465.
  • 11
    Shapiro W, Young D, Mehta B. Methotrexate distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975; 293: 161166.
  • 12
    Strong J, Collins J, Lester C, et al. Pharmacokinetics of intra-ventricular and intravenous N, N', N“-triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans. Cancer Res. 1986; 46: 61016104.
  • 13
    Chamberlain M, Corey-Bloom J. Leptomeningeal metastases: 111Indium-DTPA CSF flow studies. Neurology. 1991; 41: 17651769.
  • 14
    Glantz M, Hall WA, Cole BF, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow studies. Cancer. 1995; 75: 29192931.
  • 15
    Grossman S, Trump D, Chen D, et al. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. Ann J Med. 1982; 73: 621627.
  • 16
    Lopez J, Nassif E, Vannicola P, et al. Central nervous system pharmacokinetics of high-dose cytosine arabinoside. J Neurooncol. 1985; 3: 119124.
  • 17
    Ackland S, Schilsky R. High-dose methotrexate: a critical reappraisal. J Oncol. 1987; 5: 20172031.
  • 18
    Slevin M, Piall E, Aderne G, et al. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol. 1983; 1: 546551.
  • 19
    Savaraj N, Feun LG, Lu K, Gray K, Wang C, Loo TL. Pharmacology of intrathecal VP-16-213 in dogs. J Neurooncol. 1992; 12: 211215.
  • 20
    van der Gaast A, Sonneveld P, Mans DR, Splinter TA. Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data. Cancer Chemother Pharmacol. 1992; 29: 335337.
  • 21
    Fleischhack G, Reif S, Hasan C, Jaehde U, Hettmer S, Bode U. Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. Br J Cancer. 2001; 84: 14531459.
  • 22
    Slavc I, Schuller E, Falger J, et al. Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors. J Neurooncol. 2003; 64: 239247.
  • 23
    Slavc I, Schuller E, Falger J, et al. Tolerability of long-term intraventricular etoposide therapy with high cumulative doses in pediatric brain tumor patients [abstract]. Neurooncology.. 2003; 4: 63.
  • 24
    Miller RG Jr. Kaplan-Meier curve for survival analysis, chapter 10. In: MillerRGJr. Survival analysis. New York: John Wiley & Sons; 1981: 114118.
  • 25
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.